Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Thrombotic microangiopathy

Atypical HUS: current diagnostic and therapeutic approaches

Nature Reviews Nephrology volume 6, pages 504–506 (2010)Cite this article

Subjects

The management of patients with hemolytic uremic syndrome is challenging, and strategies for accurate diagnosis and effective treatment are needed. Intensive research over the past several years has revealed dysregulation of the complement system to be the main underlying cause of the syndrome, making this system the target of promising novel diagnostic and treatment strategies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Besbas, N. et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 70, 423–431 (2006).

    Article  CAS  Google Scholar 

  2. Taylor, C. M., Machin, S., Wigmore, S. J. & Goodship, T. H. Clinical practice guidelines for the management of atypical hemolytic uremic syndrome in the United Kingdom. Br. J. Hematol. 148, 37–47 (2010).

    Article  CAS  Google Scholar 

  3. Caprioli, J. et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108, 1267–1279 (2006).

    Article  CAS  Google Scholar 

  4. Noris, M. & Remuzzi, G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361, 1676–1687 (2009).

    Article  CAS  Google Scholar 

  5. Prufer, F. et al. Terminal complement complex (C5b–9) in children with recurrent hemolytic uremic syndrome. Semin. Thromb. Hemost. 32, 121–127 (2006).

    Article  Google Scholar 

  6. Richards, A. et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol. Immunol. 44, 111–122 (2007).

    Article  CAS  Google Scholar 

  7. Remuzzi, G. et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 100, 778–785 (2002).

    Article  CAS  Google Scholar 

  8. Loirat, C., Noris, M. & Fremeaux-Bacchi, V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr. Nephrol. 23, 1957–1972 (2008).

    Article  Google Scholar 

  9. Hillmen, P. The role of complement inhibition in PNH. Hematology Am. Soc. Hematol. Educ. Program 116–123 (2008).

    Article  Google Scholar 

  10. Zimmerhackl, L. B. et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 362, 1746–1748 (2010).

    Article  Google Scholar 

Download references

Acknowledgements

The authors' work cited in this commentary was supported by ÖNB (Austrian Research Fund), Medical University Innsbruck and GPN (German Pediatric Nephrology Society).

Author information

Authors and Affiliations

  1. Department of Pediatrics, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria

    Alejandra Rosales, Magdalena Riedl & Lothar B. Zimmerhackl

Authors
  1. Alejandra Rosales
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Magdalena Riedl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lothar B. Zimmerhackl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lothar B. Zimmerhackl.

Ethics declarations

Competing interests

L. B. Zimmerhackl declares an association with the following company: Alexion Pharmaceuticals, as consultant, recipient of speakers bureau honoraria and recipient of grant/research support. The other authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosales, A., Riedl, M. & Zimmerhackl, L. Atypical HUS: current diagnostic and therapeutic approaches. Nat Rev Nephrol 6, 504–506 (2010). https://doi.org/10.1038/nrneph.2010.98

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2010.98

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing